Retatrutide FDA Approval Status 2026: Timeline, Trials, Release Date

Retatrutide is not FDA approved for any indication as of 2026. This page is the canonical tracker for its approval status — what Phase the trials are in, when primary endpoints read out, when a regulatory filing is plausible, and what all of this means for when you can actually get retatrutide through a pharmacy.

Current FDA status

Investigational

No marketing authorization

Phase

Phase 3

TRIUMPH program

Earliest approval

2027–2028

Analyst projection

FDA approval timeline

Phase 1 Safety · 2019–2020 Healthy volunteers, single/multi dose

Phase 2 TRIUMPH-1 · 2022–2023 338 adults · 24.2% weight loss at 48w

Phase 3 TRIUMPH-3, 4, 5 · 2023–2026 Obesity + T2D + Parkinson's · ~5,000 participants

FDA filing Expected late 2026 or 2027 Projected BLA submission

FDA approval Projected 2027 or later No guarantees — subject to data & review

Phase 3 retatrutide clinical trials (enrolling 2026)

Trial	NCT ID	Indication	Size	Status
TRIUMPH-3	NCT05929066	Obesity + CVD	~1,800	Enrolling / follow-up
TRIUMPH-4	NCT05929079	Obesity + knee OA	~1,300	Enrolling / follow-up
TRIUMPH-5	NCT06383390	Adolescent obesity	~160	Enrolling
TRIUMPH-PD	NCT05930535	Parkinson's disease	TBD	Enrolling
T2D follow-on	TBD	Type 2 diabetes	TBD	Planned

Eligibility and site locations are listed at ClinicalTrials.gov (search by NCT number). Enrollment is competitive.

Phase 2 results recap (TRIUMPH-1)

The most recent published retatrutide data is TRIUMPH-1, the Phase 2 trial in 338 adults with obesity (Jastreboff et al., NEJM July 2023). Primary endpoint was percent change in body weight at 48 weeks.

12 mg weight loss

−24.2%

Highest dose arm

≥15% loss

83%

12 mg arm

≥25% loss

26%

12 mg arm

Baseline BMI

37.3

Trial population

Source: New England Journal of Medicine 2023.

What happens between now and FDA approval

Phase 3 primary readout. Expected 2026 for obesity-focused trials. If weight-loss and safety endpoints match Phase 2, filing momentum builds.
BLA submission. Eli Lilly files a Biologics License Application with the FDA. For priority-review drugs this can happen shortly after primary readouts.
FDA review. 6 months for priority review, 10 months for standard review. Weight-management indications have historically received standard review.
PDUFA date. FDA issues a Prescription Drug User Fee Act target action date — the deadline for approval decision.
Approval or complete response letter. Approval triggers launch; a CRL triggers additional data requests and delay.
Launch and supply ramp. Even approved, initial supply is typically capacity-constrained for 6–18 months (Zepbound and Wegovy patterns).

Retatrutide FDA approval status month-by-month

January 2026

Phase 3 TRIUMPH-3 and TRIUMPH-4 continue enrolling. Lilly Q4 2025 earnings reiterated retatrutide as a pipeline priority. No filing date announced.

February 2026

No regulatory milestones. Interim safety monitoring continues. Peptide community signal: compounding-pharmacy retatrutide access tightening after FDA guidance updates.

March 2026

Lilly Q1 reports progress on TRIUMPH-5 adolescent trial. Phase 2 MASH substudy data presented at AACE.

April 2026 (current)

Tracker status: no approval, Phase 3 ongoing. Next meaningful milestone: Lilly Q2 earnings (July) and potential ADA 2026 presentation of Phase 3 interim data.

Retatrutide for Parkinson's disease

A growing research interest is whether retatrutide's triple-agonist mechanism can slow motor progression in early Parkinson's disease. The hypothesis rests on the neurometabolic effects of GLP-1 and glucagon receptor activation: improved mitochondrial function in dopaminergic neurons, reduced neuroinflammation, and better cerebral glucose utilization.

TRIUMPH-PD (NCT05930535) is an ongoing Phase 2 exploratory trial. Primary endpoint is MDS-UPDRS motor score change over 48 weeks. This is not a registrational trial — even if positive, a separate Phase 3 program would be required before Parkinson's approval.

Related pre-retatrutide data from exenatide (a GLP-1 only agonist) showed modest motor benefit in Parkinson's trials, sparking the broader hypothesis. Retatrutide's additional GIP and glucagon activity may amplify the neuroprotective signal — or not. TRIUMPH-PD will clarify.

Eli Lilly retatrutide news and pipeline context

Eli Lilly continues to invest heavily in its obesity pipeline. Beyond retatrutide, Lilly is developing orforglipron (an oral GLP-1, Phase 3), bimagrumab (an anti-myostatin combination partner, Phase 2), and several next-generation incretins. Retatrutide is positioned as Lilly's "flagship" future obesity drug — the successor to tirzepatide.

Manufacturing scale-up is already underway. Lilly invested ~$13 billion in manufacturing capacity over 2022–2024, partly to support tirzepatide demand and partly to prepare for retatrutide launch.

FDA status FAQ

Frequently asked questions

Is retatrutide FDA approved?

No. As of 2026, retatrutide is not approved by the FDA, EMA, or any other regulator. It is an investigational drug in Phase 3 clinical trials.

When will retatrutide be FDA approved?

No firm date. Eli Lilly has not publicly committed to a filing date. Industry analysts expect a Biologics License Application (BLA) submission in late 2026 or 2027, followed by a 6–10 month FDA review. Realistic earliest approval window: late 2027 to 2028, assuming Phase 3 trials hit their endpoints.

When will retatrutide be available?

After FDA approval — so probably 2027–2028 at the earliest. Initial availability will likely be limited by manufacturing capacity (same pattern as Zepbound and Wegovy launches). Broad access typically follows 12–18 months after launch.

What's the retatrutide FDA approval timeline?

Phase 3 trials are running through 2025–2026. Primary endpoint readouts expected 2026–2027. BLA submission likely 2026–2027. FDA priority review: 6 months; standard review: 10 months. Earliest approval window: late 2027 to 2028.

Can I sign up for a retatrutide clinical trial?

Yes. Active Phase 3 trials are enrolling. TRIUMPH-3 (NCT05929066, obesity + CV disease), TRIUMPH-4 (NCT05929079, obesity + knee osteoarthritis), TRIUMPH-5 (NCT06383390, adolescent obesity), and TRIUMPH-PD (NCT05930535, Parkinson's disease). Search your zip code at ClinicalTrials.gov.

What are the retatrutide Phase 3 results?

Not released yet. Phase 3 trials are ongoing with primary readouts expected in 2026–2027. Interim safety data continues to match Phase 2 patterns. Lilly updates investors quarterly — check the investor relations page for the latest.

Is retatrutide approved in Parkinson's disease?

No. TRIUMPH-PD (NCT05930535) is a Phase 2 exploratory trial testing whether retatrutide's glucagon/GIP activity provides neuroprotection in early Parkinson's disease. This is a small proof-of-concept study, not a registrational trial. Approval for Parkinson's, if it ever comes, is many years away.

Has Eli Lilly said anything about retatrutide release date?

Eli Lilly earnings calls and investor presentations have mentioned retatrutide as a priority pipeline asset without committing to a specific release date. The company has signaled potential Phase 3 readouts in 2026 with possible regulatory filings to follow.

Retatrutide FDA status: investigational. Phase 3 ongoing. Approval 2027–2028.